CO6480943A2 - Nuevas sales de fumarato de un antagonista del receptor de histamina h3 - Google Patents

Nuevas sales de fumarato de un antagonista del receptor de histamina h3

Info

Publication number
CO6480943A2
CO6480943A2 CO11177476A CO11177476A CO6480943A2 CO 6480943 A2 CO6480943 A2 CO 6480943A2 CO 11177476 A CO11177476 A CO 11177476A CO 11177476 A CO11177476 A CO 11177476A CO 6480943 A2 CO6480943 A2 CO 6480943A2
Authority
CO
Colombia
Prior art keywords
salts
new smoke
histamine
receiver antagonist
antagonist
Prior art date
Application number
CO11177476A
Other languages
English (en)
Inventor
Beverly Langevin
Robert Allan Farr
Dinubhai H Shah
Daniel Sherer
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of CO6480943A2 publication Critical patent/CO6480943A2/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10Drugs for genital or sexual disorders; Contraceptives for impotence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Reproductive Health (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Anesthesiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Otolaryngology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La descripción se refiere e sales de fumarato de 2-(ciclohexilmetil)-N-{2-[(2S)-1- metilpirrolidin-2-iI]etil}-1,23,4-tetrahidroisoquinolina-7-sulfonamida, a sus composiciones farmacéuticas, procedimientos para elaborarlas y a sus métodos de uso.
CO11177476A 2009-06-26 2011-12-23 Nuevas sales de fumarato de un antagonista del receptor de histamina h3 CO6480943A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US22068309P 2009-06-26 2009-06-26
FR0959110 2009-12-17

Publications (1)

Publication Number Publication Date
CO6480943A2 true CO6480943A2 (es) 2012-07-16

Family

ID=43386878

Family Applications (1)

Application Number Title Priority Date Filing Date
CO11177476A CO6480943A2 (es) 2009-06-26 2011-12-23 Nuevas sales de fumarato de un antagonista del receptor de histamina h3

Country Status (25)

Country Link
US (1) US8664245B2 (es)
EP (1) EP2445899B1 (es)
JP (1) JP6053519B2 (es)
KR (1) KR101804749B1 (es)
CN (1) CN102803247B (es)
AR (1) AR077223A1 (es)
AU (1) AU2010264422B2 (es)
BR (1) BRPI1011258A2 (es)
CA (1) CA2766154C (es)
CO (1) CO6480943A2 (es)
DO (1) DOP2011000398A (es)
ES (1) ES2587064T3 (es)
IL (1) IL216924A0 (es)
MA (1) MA33378B1 (es)
MX (1) MX2011012824A (es)
NZ (1) NZ597219A (es)
PE (1) PE20121403A1 (es)
PL (1) PL2445899T3 (es)
RU (1) RU2537847C2 (es)
SG (1) SG176645A1 (es)
TN (1) TN2011000620A1 (es)
TW (1) TWI462915B (es)
UY (1) UY32738A (es)
WO (1) WO2010151611A1 (es)
ZA (1) ZA201108838B (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR080374A1 (es) 2010-03-05 2012-04-04 Sanofi Aventis Procedimiento para la preparcion de 2-(ciclohexilmetil)-n-(2-((2s)-1-metilpirrolidin-2-il) etil)- 1,2,3,4-tetrahidroisoquinolin-7- sulfonamida
WO2013151982A1 (en) 2012-04-03 2013-10-10 Arena Pharmaceuticals, Inc. Methods and compounds useful in treating pruritus, and methods for identifying such compounds
EP2647377A1 (en) 2012-04-06 2013-10-09 Sanofi Use of an h3 receptor antagonist for the treatment of alzheimer's disease
JP2015524400A (ja) * 2012-07-19 2015-08-24 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 9−[4−(3−クロロ−2−フルオロ−フェニルアミノ)−7−メトキシ−キナゾリン−6−イルオキシ]−1,4−ジアザ−スピロ[5.5]ウンデカン−5−オンのフマル酸塩、その薬物としての使用及び調製
SG11201601306QA (en) * 2013-09-09 2016-03-30 Sanofi Sa An h3 receptor antagonist combined with a cholinesterase inhibitor for use in the treatment of alzheimer's disease

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4228170A (en) 1979-08-30 1980-10-14 Smithkline Corporation 7- and/or 8-Sulfur substituted 1,2,3,4-tetrahydroisoquinoline compounds
EP0306375A1 (fr) 1987-08-07 1989-03-08 Synthelabo Dérivés de[(pipéridinyl-4)méthyl]-2 tétrahydro-1,2,3,4 isoquinoléine, leur préparation et leur application en thérapeutique
IL89156A (en) 1988-07-12 1993-05-13 Synthelabo Derivatives of 2-((4-piperidinyl) methyl)- 1,2,3,4- tetrahydroisoquinoline, their preparation and their application in therapeutics
SK1212002A3 (en) 1999-07-29 2002-11-06 Egyt Gyogyszervegyeszeti Gyar Isoquinoline derivatives, pharmaceutical compositions containing the same, and a process for the preparation of the active substance
US6825198B2 (en) * 2001-06-21 2004-11-30 Pfizer Inc 5-HT receptor ligands and uses thereof
AU2002358700A1 (en) 2001-12-26 2003-07-15 Bayer Aktiengesellschaft Urea derivatives as vr1- antagonists
US7790231B2 (en) 2003-07-10 2010-09-07 Brewer Science Inc. Automated process and apparatus for planarization of topographical surfaces
FR2870846B1 (fr) * 2004-05-25 2006-08-04 Sanofi Synthelabo Derives de tetrahydroisoquinolylsulfonamides, leur preparation et leur utilisation en therapeutique
CA2602336A1 (en) * 2005-03-31 2006-10-05 Ucb Pharma S.A. Compounds comprising an oxazole or thiazole moiety, processes for making them, and their uses
CA2645731A1 (en) * 2006-03-15 2007-09-27 Wyeth N-substituted-azacyclylamines as histamine-3 antagonists
PE20081152A1 (es) * 2006-10-06 2008-08-10 Wyeth Corp Azaciclilaminas n-sustituidas como antagonistas de histamina-3
US7846930B2 (en) * 2007-05-18 2010-12-07 Janssen Pharmaceutica Nv Diaryl-substituted tetrahydroisoquinolines as histamine H3 receptor and serotonin transporter modulators
PE20090812A1 (es) * 2007-07-16 2009-06-14 Wyeth Corp Derivados de aminoalquilazol como antagonistas de histamina-3

Also Published As

Publication number Publication date
US8664245B2 (en) 2014-03-04
PL2445899T3 (pl) 2017-08-31
AU2010264422A1 (en) 2012-02-02
ES2587064T3 (es) 2016-10-20
MX2011012824A (es) 2012-01-27
MA33378B1 (fr) 2012-06-01
UY32738A (es) 2011-01-31
CN102803247B (zh) 2014-11-05
CA2766154C (en) 2015-04-07
RU2012102671A (ru) 2013-08-10
KR20120039555A (ko) 2012-04-25
TW201103911A (en) 2011-02-01
ZA201108838B (en) 2012-08-29
NZ597219A (en) 2013-05-31
WO2010151611A1 (en) 2010-12-29
EP2445899B1 (en) 2016-05-11
KR101804749B1 (ko) 2017-12-05
BRPI1011258A2 (pt) 2016-03-22
CA2766154A1 (en) 2010-12-29
RU2537847C2 (ru) 2015-01-10
AR077223A1 (es) 2011-08-10
DOP2011000398A (es) 2012-01-31
JP2012531424A (ja) 2012-12-10
CN102803247A (zh) 2012-11-28
TWI462915B (zh) 2014-12-01
US20120149728A1 (en) 2012-06-14
IL216924A0 (en) 2012-03-01
SG176645A1 (en) 2012-01-30
PE20121403A1 (es) 2012-11-02
EP2445899A1 (en) 2012-05-02
AU2010264422B2 (en) 2014-12-18
TN2011000620A1 (en) 2013-05-24
JP6053519B2 (ja) 2016-12-27

Similar Documents

Publication Publication Date Title
GT201300159A (es) Composiciones y metodos para modular el fxr
UY35998A (es) 1-(3-(tert-BUTIL)1-(p-TOLIL)-1H-PIRAZOL-5-IL)-3-(4-((2-((6-ETILPIRAZIN-2-IL)AMINO)PIRIDIN-4-IL)METOXI)NAFTALEN-1-IL) UREA Y SUS SALES DERIVADAS FARMACÉUTICAMENTE ACEPTABLES, COMO INHIBIDORES DE P38 M AP QUINASA
CL2012001911A1 (es) Compuestos derivados de fumarato; composicion farmaceutica que los comprende; y su uso en el tratamiento de una enfermedad inflamatoria o neurodegenerativa.
UY32296A (es) Nuevos compuestos
CR10963A (es) Compuestos de 2-amino pirimidina
EA201290355A1 (ru) Спиропиперидиновые соединения в качестве антагонистов рецептора orl-1
CO6480943A2 (es) Nuevas sales de fumarato de un antagonista del receptor de histamina h3
ECSP088700A (es) Acidos 4-fenil-tiazol-5-carboxilicos y amidas de acidos 4-fenil-tiazol-5-carboxilicos como inhibidores de la plk1
EA201590823A1 (ru) 6-((s)-1-{1-[5-(2-гидроксиэтокси)пиридин-2-ил]-1h-пиразол-3-ил}этил)-3h-1,3-бензотиазол-2-он в качестве антагониста tarp-гамма 8-зависимого ampa-рецептора
EA201600436A1 (ru) Кристаллическая солевая форма (s)-(2-(6-хлор-7-метил-1h-бензо[d]имидазол-2-ил)-2-метилпирролидин-1-ил)(5-метокси-2-(2h-1,2,3-триазол-2-ил)фенил)метанона и ее применение в качестве антагонистов орексинового рецептора
ES2572368T3 (es) Tratamiento de la artrosis
SV2011003854A (es) Derivados de piperazina que se unen a las placas amiloides para obtener imagenes de las mismas y su uso
UY32042A (es) Compuestos de 2-aminopirimidina como potentes inhibidores de hsp-90
CO6630129A2 (es) Procedimiento para la preparación de 2-(ciclohexilmetil)-n-{2-[(2s)-1- metilpirrolidin-2-il]etil}-1,2,3,4-tetahidroisoquinolina-71sulfonamida
AR069009A1 (es) Arilindenopirimidinas y su uso como antagonistas del receptor a₂a de adenosina
CY1118841T1 (el) Παραγωγα αμινοκυκλοβουτανιου, μεθοδος παρασκευης αυτων και η χρηση αυτων ως φαρμακα
ATE546448T1 (de) Urotensin-ii-rezeptorantagonisten
BR112012030004A2 (pt) antagonistas não competitivos de receptor nicotínico
AR090605A1 (es) Un antagonista del receptor h3 para uso en el tratamiento de la enfermedad de alzheimer
ECSP11011547A (es) Nuevas sales de fumarato de un antagonista del receptor de histamina h3
UY34316A (es) Inhibidores heterocíclicos de los receptores de histamina para el tratamiento de una enfermedad
EA201301136A2 (ru) Новый способ синтеза (2e)-3-(3,4-диметоксифенил)проп-2-еннитрила, применение в синтезе ивабрадина и его фармацевтически приемлемых кислотно-аддитивных солей
NI201100210A (es) Nuevas sales de fumarato de un antagonista del receptor de histamina h3.
UA106380C2 (ru) Фумаратные соли антагониста гистаминового рецептора н3
NI201200127A (es) Procedimiento para la preparación de 2 - ( ciclohexilmetil ) - n - { 2 - [ (2s) - 1 - metilpirrolidin - 2 - il ] etil } - 1, 2, 3, 4 - tetrahidroisoquinolin - 7 - sulfonamida.

Legal Events

Date Code Title Description
FC Application refused